New drug combo shows promise for tough prostate cancer
NCT ID NCT03787680
First seen Mar 27, 2026 · Last updated May 05, 2026 · Updated 7 times
Summary
This study tests whether combining two drugs, olaparib and AZD6738, can shrink tumors or lower PSA levels in men with advanced prostate cancer that no longer responds to hormone therapy. About 49 men with metastatic castration-resistant prostate cancer will receive the drug combination. The goal is to see how well the treatment works and how safe it is.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Michigan Hospital
Ann Arbor, Michigan, 48109, United States
-
University of Virginia Health System
Charlottesville, Virginia, 22908, United States
-
Wayne State University/Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
Conditions
Explore the condition pages connected to this study.